Teva’s Austedo wins US nod for Huntington’s patients
US regulators have green-lighted Teva Pharmaceutical Industries’ Austedo for the treatment of chorea associated with Huntington’s disease (HD), offering patients the first new treatment option in nearly a decade.
Read More
